| SARS-CoV-2 mRNA vaccine design enabled by prototype pathogen preparedness KS Corbett, DK Edwards, SR Leist, OM Abiona, S Boyoglu-Barnum, ... Nature 586 (7830), 567-571, 2020 | 1484 | 2020 |
| Serum neutralizing activity elicited by mRNA-1273 vaccine K Wu, AP Werner, M Koch, A Choi, E Narayanan, GBE Stewart-Jones, ... New England Journal of Medicine 384 (15), 1468-1470, 2021 | 481 | 2021 |
| Role of toll-like receptors in changes in gene expression and NF-κB activation in mouse hepatocytes stimulated with lipopolysaccharide S Liu, DJ Gallo, AM Green, DL Williams, X Gong, RA Shapiro, ... Infection and immunity 70 (7), 3433-3442, 2002 | 305 | 2002 |
| A lipid-encapsulated mRNA encoding a potently neutralizing human monoclonal antibody protects against chikungunya infection N Kose, JM Fox, G Sapparapu, R Bombardi, RN Tennekoon, AD De Silva, ... Science immunology 4 (35), eaaw6647, 2019 | 195 | 2019 |
| RosettaBackrub—a web server for flexible backbone protein structure modeling and design F Lauck, CA Smith, GF Friedland, EL Humphris, T Kortemme Nucleic acids research 38 (suppl_2), W569-W575, 2010 | 147 | 2010 |
| Design of multi-specificity in protein interfaces EL Humphris, T Kortemme PLoS computational biology 3 (8), e164, 2007 | 120 | 2007 |
| A multiclade env–gag VLP mRNA vaccine elicits tier-2 HIV-1-neutralizing antibodies and reduces the risk of heterologous SHIV infection in macaques P Zhang, E Narayanan, Q Liu, Y Tsybovsky, K Boswell, S Ding, Z Hu, ... Nature medicine 27 (12), 2234-2245, 2021 | 100 | 2021 |
| Prediction of protein-protein interface sequence diversity using flexible backbone computational protein design EL Humphris, T Kortemme Structure 16 (12), 1777-1788, 2008 | 100 | 2008 |
| Variant SARS-CoV-2 mRNA vaccines confer broad neutralization as primary or booster series in mice K Wu, A Choi, M Koch, S Elbashir, LZ Ma, D Lee, A Woods, C Henry, ... Vaccine, 2021 | 91 | 2021 |
| Discovery of a novel amino lipid that improves lipid nanoparticle performance through specific interactions with mRNA M Cornebise, E Narayanan, Y Xia, E Acosta, L Ci, H Koch, J Milton, ... Advanced Functional Materials 32 (8), 2106727, 2022 | 55 | 2022 |
| Salmonella vaccines N Cohen, MAA Messou, S Calabrese, E Narayanan US Patent App. 16/180,076, 2019 | 53 | 2019 |
| Structural and mechanistic exploration of acid resistance: kinetic stability facilitates evolution of extremophilic behavior BA Kelch, KP Eagen, FP Erciyas, EL Humphris, AR Thomason, S Mitsuiki, ... Journal of molecular biology 368 (3), 870-883, 2007 | 51 | 2007 |
| Epstein-barr virus vaccines G Ciaramella, S John, E Narayanan, B Bollman US Patent App. 16/765,285, 2020 | 40 | 2020 |
| Rna bacterial vaccines E Narayanan, N Cohen, G Ciaramella US Patent App. 16/496,135, 2020 | 40 | 2020 |
| Discrete RNA libraries from pseudo-torsional space E Humphris-Narayanan, AM Pyle Journal of molecular biology 421 (1), 6-26, 2012 | 34 | 2012 |
| A new way to see RNA KS Keating, EL Humphris, AM Pyle Quarterly reviews of biophysics 44 (4), 433-466, 2011 | 29 | 2011 |
| Chimeric fusion (F) and attachment (G) glycoprotein antigen delivery by mRNA as a candidate Nipah vaccine RJ Loomis, AT DiPiazza, S Falcone, TJ Ruckwardt, KM Morabito, ... Frontiers in Immunology 12, 772864, 2021 | 27 | 2021 |
| Prediction of mutational tolerance in HIV-1 protease and reverse transcriptase using flexible backbone protein design E Humphris-Narayanan, E Akiva, R Varela, S Ó Conchúir, T Kortemme Public Library of Science 8 (8), e1002639, 2012 | 25 | 2012 |
| Solving nucleic acid structures by molecular replacement: examples from group II intron studies M Marcia, E Humphris-Narayanan, KS Keating, S Somarowthu, ... Acta Crystallographica Section D: Biological Crystallography 69 (11), 2174-2185, 2013 | 21 | 2013 |
| Hiv rna vaccines P Lusso, P Zhang, E Narayanan, SM Elbashir US Patent App. 17/439,198, 2022 | 12 | 2022 |
